BenzingaSeptember 23, 2026 at 5:17 AM NYLast Month
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
